Data / Form D filings / ARDELYX, INC.
ARDELYX, INC.: Form D filings
ARDELYX, INC., a pharmaceuticals company in Fremont, CA, filed 4 Form D notices with the SEC between 2010 and 2016. The latest, on August 1, 2016, reports $110 million sold of a $110 million offering to 31 investors.
Find out what ARDELYX, INC. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 34175 ARDENWOOD BLVD., SUITE 200, Fremont, CA, 94555
- Phone
- (510) 745-7047
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1437402
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 1, 2016 | New notice | $110,000,008 | $110,000,008 | $0 | 31 | Jul 18, 2016 | sec.gov |
| Jun 22, 2015 | New notice | $107,996,652 | $77,771,627 | $30,225,025 | 11 | Jun 5, 2015 | sec.gov |
| Jul 7, 2011 | New notice | $22,283,445 | $17,578,665 | $4,704,780 | 11 | Jun 23, 2011 | sec.gov |
| Dec 8, 2010 | New notice | $10,027,388 | $5,013,694 | $5,013,694 | 11 | Nov 16, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Annalisa Jenkins | Director | |
| Paul Korner | Executive Officer | |
| David Mott | Director | |
| David Rosenbaum | Executive Officer | |
| Elizabeth Grammer | Executive Officer | |
| Michael Raab | Executive Officer, Director | |
| Gordon Ringold | Director | |
| Robert Bazemore | Director | |
| Richard Rodgers | Director | |
| Jeff Jacobs | Executive Officer | |
| Mark Kaufmann | Executive Officer | |
| William Bertrand, Jr. | Director | |
| Jeremy Caldwell | Executive Officer |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Aug 1, 2016 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what ARDELYX, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.